Article PDF
Avoid common mistakes on your manuscript.
References
Drazen JM. COX-2 inhibitors—a lesson in unexpected problems (Editorial). N Engl J Med 2005; 352:1131- 2.
Psaty BM, Furberg CD. COX-2 inhibitors—lessons in drug safety (Editorial). N Engl J Med 2005; 352:1133–5.
Mangano DT, Tudor IC, Dietzel C;Multicenter Study of Perioperative Ischemia Research Group: Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354:353–65.
Tanaka Y, Ward SL, Smith WL. Immunochemical and kinetic evidence for two different prostaglandin H- prostaglandin E isomerases in sheep vesicular gland microsomes. J Biol Chem 1987; 262:1374–81.
McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96:272–7.
Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286:954–9.
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343:1520–8.
Solomon SD, McMurray JJ, Pfeffer MA, et al. ;Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071–80.
Martin BK, Meinert CL, Breitner JC ;(ADAPT Research Group). Double placebo design in a prevention trial for Alzheimer’s disease. Control Clin Trials 2002; 23:93–9.
Bresalier RS, Sandler RS, Quan H, et al. ;Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092–102.
Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352:1081–91.
Konstantinopoulos PA, Lehmann DF. The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. J Clin Pharmacol 2005; 45:742–50.
Brophy JM. Cardiovascular risk associated with celecoxib (Letter, reply). N Engl J Med 2005; 352:2648- 50.
Rossouw JE, Anderson GL, Prentice RL, et al. ;Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288:321–33.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stafford-Smith, M. Hurry up and slow down: Lessons in drug development from the COX-2 inhibitors. Can J Anesth 53, 973–977 (2006). https://doi.org/10.1007/BF03022524
Issue Date:
DOI: https://doi.org/10.1007/BF03022524